Camostat Mesylate May Reduce Severity of Coronavirus Disease 2019 Sepsis: A First Observation.

ABSTRACT: Severe acute respiratory syndrome coronavirus 2 cell entry depends on angiotensin-converting enzyme 2 and transmembrane serine protease 2 and is blocked in cell culture by camostat mesylate, a clinically proven protease inhibitor. Whether camostat mesylate is able to lower disease burden in coronavirus disease 2019 sepsis is currently unknown.

Design

Retrospective observational case series.

Setting

Patient treated in ICU of University hospital Göttingen, Germany.

Patients

Eleven critical ill coronavirus disease 2019 patients with organ failure were treated in ICU.

Interventions

Compassionate use of camostat mesylate (six patients, camostat group) or hydroxychloroquine (five patients, hydroxychloroquine group).

Measurements and main results

Clinical course

SUBMITTER: Hofmann-Winkler H 

PROVIDER: S-EPMC7671878 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature